p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 57, Issue 4, 1997, Pages 281-289

  Ollikainen, H ^a,b   Syrjanen S ^c   Koskela, K ^a,b   Pelliniemi, T T ^b   Pulkki, K ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Multiple myeloma; p53; PCR; SSCP

Indexed keywords

PROTEIN P53;

ARTICLE; BLOOD ANALYSIS; BONE MARROW CELL; CELL CULTURE; CELL LINE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0030754557     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709099401     Document Type: Article

References (40)

1. Levine AJ, Momand J. Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
2. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
3. Chen P-L, Chen Y, Bookstein R, Lee W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576-80.
4. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
5. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
6. Shen Y, Shenk T. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci USA 1994; 91: 8940-4.
7. Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. P53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995; 55: 4420-4.
8. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995; 14: 5638-45.
9. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992; 89: 7262-6.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
11. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990; 5: 945-52.
12. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley EH, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
13. Imamura J, Miyoshi I, Koeffler HP. p53 in hematological malignancies. Blood 1994; H4: 2412-21.
14. Newcomb EW. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leukemia Lymphoma 1995; 17: 211-21.
15. Reich NC, Levine AJ. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature 1984; 308: 199-201.
16. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, et al. P53 and kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992; 52: 2610-15.
17. Kennedy SM, MacGeogh C, Jaffe R, Spurr NK. Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 1994; 25: 438-42.
18. Greco C, Gandolfo GM, Mattei F, Gradilone A, Alvino S, Pastore LL. Detection of c-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions. Anticancer Res 1994; 14: 1433-40.
19. Luo J-C, Zehab R, Anttila R, Ridanpää M, Husgafvel-Pursiainen K, Vainio H. Detection of serum p53 protein in lung cancer patients. J Occup Med 1994; 36: 155-60.
20. Braun A, Strait K, Konietzko N, Wiesner B, Loeffler S, Presek P, et al. Detection of oncogene and tumor suppressor gene products in serum of former uranium miners for secondary prevention of radon-induced lung cancer. Clin Chem 1995; 41: 1913-15.
21. Partanen R, Koskinen H, Oksa P, Hemminki K, Carney W, Smith S, et al. Serum oncoproteins in asbestosis patients. Clin Chem 1995; 41: 1844-7.
22. Pulkki K, Ollikainen H, Rajamäki A, Pelliniemi T-T. Serum p53 oncoprotein and p53 antibodies as prognostic factors in multiple myeloma (MM). Blood 1995; 86 Suppl: 64a.
23. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-54.
24. Koskela K, Pelliniemi T-T, Remes K, Savino R, Ciliberto G, Pulkki K. Establishment of three new myeloma cell lines from bone marrow plasma cells: response to interleukin-6 and interleukin-6-antagonist. Vth international workshop on multiple myeloma, La Baule, France, 10-13 September 1995, Meeting Abstract 3.83.
25. Puranen M, Saarikoski S, Syrjänen K, Syrjänen S. Polymerase chain reaction amplification of human papillomavirus DNA from archival, Papanicolau-stained cervical smears. Acta Cytol 1996; 40: 391-5.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
27. Buchman VL, Chumakov PM, Ninkina NN, Samarine OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70: 245-252.
28. Kurvinen K, Hietanen S, Syrjänen K, Syrjänen S. Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem™. J Virol Methods 1995; 51: 43-54.
29. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991; 6: 873-5.
30. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, et al. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 1993; 14: 833-9.
31. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-7.
32. Pelliniemi T-T, Irjala K, Mattila K, Pulkki K, Rajamäki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995; 85: 765-71.
33. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphism of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-70.
34. Preudhomme C, Facon T, Zandecki M, Vanrumbeke M, Lay JL, Nataf E. et al. Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol 1992; 81: 440-3.
35. Portier M, Molès J-P, Mazars G-R, Jeanteur P, Bataille R, Klein B, et al. p53 and ras gene mutations in multiple myeloma. Oncogene 1992; 7: 2539-43.
36. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128-35.
37. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 1994; 8: 758-67.
38. Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K, Aokia N. N-ras and p53 mutations are very rare events in multiple myeloma. Int J Hematol 1995; 62: 91-7.
39. Mazars G-R, Portier M, Zhang X-G, Jourdan M, Bataille R, Theillet C, et at. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 1015-18.
40. Hayashi K. PCR-SSCP: a method for detection of mutations. GATA 9, 73-9.